The Filing Desk

Harrow vs Puma Biotechnology

Harrow HROW · Puma Biotechnology PBYI · Pharmaceuticals

Harrow reported revenue of $272 million in fiscal 2025, 1.2 times Puma Biotechnology's $228 million in fiscal 2025. Harrow's revenue grew 36.4% in its latest year, and Puma Biotechnology's fell 0.9%. Harrow had an operating margin of 11.2%, against 16.3% at Puma Biotechnology. Free cash flow was $43 million at Harrow and $42 million at Puma Biotechnology.

Side by side

HarrowPuma Biotechnology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$272M$228M
Revenue growth36.4%−0.9%
Revenue growth a year, last 5 years41.0%0.3%
Gross margin75.0%74.5%
Operating margin11.2%16.3%
Net margin−1.9%13.6%
Free cash flow$43M$42M
Free cash flow margin15.8%18.3%
Return on capital—48.2%
Net debt to EBITDA5.5x−1.4x
Dividends and buybacks$0M$0M
Change in diluted share count3.1%3.2%
Last close$30.12$7.77
P/E at the last close—16.9×
Insider trades, last 12 months——
Piotroski F-score6 of 98 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
HarrowPuma Biotechnology
Operating margin
Percent of revenue
HarrowPuma Biotechnology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
HarrowPuma Biotechnology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Harrow and Puma Biotechnology pages.